Ametic

Quick links to important sections

Ametic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ametic

Quick Facts

Property Description
Active Ingredient (INN) Metoclopramide (as Metoclopramide Hydrochloride)
Pharmaceutical Class Prokinetic Agent, Dopamine Antagonist Antiemetic
Origin / Type Synthetic Compound, Benzamide Derivative
Available Forms Oral tablets, Oral solutions, Injectable solutions
General Purpose Controlling nausea and enhancing upper gastrointestinal motility

Defining Ametic: Pharmacological Class and Function

Ametic is a pharmaceutical product containing the active ingredient Metoclopramide, which is primarily classified as both a prokinetic agent and a Dopamine D2 receptor antagonist antiemetic. Its general purpose is to provide relief by suppressing the central nervous system signals that trigger vomiting and by correcting impaired movement of the upper digestive tract. Metoclopramide is used in treating and preventing various types of vomiting and is an agent utilized in functional gastrointestinal disorders. The prokinetic function is crucial, as Metoclopramide enhances the contraction and coordination of gastrointestinal muscle, accelerating the rate of gastric emptying. This dual activity positions it as a tool for managing symptoms rooted in a combination of central nausea signaling and functional digestive delays.

Composition, Origin, and Available Pharmaceutical Forms

The active substance, Metoclopramide, is an International Nonproprietary Name (INN) for a synthetic compound chemically derived from benzamide. This indicates that the drug's properties are the result of laboratory synthesis, not natural extraction. Metoclopramide is utilized in both hospital and outpatient settings. It is typically formulated as the stable salt, Metoclopramide Hydrochloride. As a single-ingredient medicine, Ametic is prepared across various dosage forms designed for different administrative routes. These preparations include oral tablets, which are used for outpatient management, and sterile injectable solutions (ampoules), which are primarily used in controlled medical environments. The drug can be administered orally (enteral), or via intravenous or intramuscular (parenteral) injection, depending on the therapeutic need.

Regulatory References

  1. Metoclopramide - LiverTox

What side effects are possible with Ametic?

Possible Side Effects and Safety Information

The official safety profile for Ametic, containing metoclopramide, outlines adverse reactions categorized primarily by system-organ class and frequency, as documented by government health authorities. The most frequently reported effects are concentrated in the nervous system.

Officially Classified Adverse Reactions

Side effects are officially classified into frequency categories:

  • Very Common (≥1/10): Restlessness (akathisia), drowsiness, fatigue, and lassitude.
  • Common (≥1/100 to <1/10): Diarrhea and asthenia.

Serious Neurological and Movement Disorders

The regulatory label documents risks associated with movement disorders. The medication carries a known risk of Extrapyramidal Symptoms (EPS), which can manifest as acute dystonic reactions. These acute effects may occur after a single administration and are often observed at the beginning of treatment. Of significant concern is the risk of Tardive Dyskinesia (TD), a potentially irreversible movement disorder associated with prolonged use. Due to this risk, treatment duration should generally not exceed 12 weeks.

Rare but serious reactions also include Neuroleptic Malignant Syndrome (NMS) and severe cardiovascular events such as severe bradycardia, circulatory collapse, and cardiac arrest, particularly following rapid intravenous administration.

Population-Specific Safety Notes

Safety statements include specific considerations for vulnerable groups. The medicine is contraindicated in children under 1 year of age due to an increased risk of extrapyramidal disorders and methemoglobinemia. Older adults are noted to have an increased risk of Tardive Dyskinesia. Furthermore, official labeling advises that a dose reduction is recommended for patients with renal impairment or severe hepatic impairment to prevent drug accumulation.

Overdose and Emergency Response

Ametic overdose is officially documented in regulatory information as potentially leading to significant central nervous system and systemic disturbances. Documented manifestations include disorientation, confusion, drowsiness, and hallucinations. A key symptom cluster reported is the emergence of extrapyramidal reactions (EPS), which involve involuntary movements, acute dystonia, and can progress to convulsions or seizures.

Overdose may lead to severe, life-threatening outcomes, including cardio-respiratory arrest, circulatory collapse, and the development of Neuroleptic Malignant Syndrome (NMS). Methemoglobinemia is a documented hematologic risk, particularly in neonates.

Regulators mandate that individuals must seek immediate medical attention or contact a Poison Control Center upon suspicion of overdose. Emergency services must be contacted immediately if the affected person collapses, experiences a seizure, or has severe trouble breathing.

Official treatment is strictly symptomatic and supportive, as no general specific antidote is known for the drug's toxicity. Continuous monitoring of cardiovascular and respiratory functions is required. Symptomatic management for EPS involves administering specific medicinal products, such as benzodiazepines. Regulatory documents also note that dialysis is not likely to be an effective measure for drug removal. Specific patient considerations exist for those with severe renal impairment, where drug clearance is reduced.

Therapeutic Uses of Ametic

Ametic is a therapeutic option utilized for the management of nausea and vomiting in several clinical situations. The medication is used to reduce the occurrence and severity of these symptoms, supporting patient comfort during treatment or recovery.

The medication's primary applications include addressing discomfort associated with chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV) following surgical procedures. It is also used to manage symptoms related to radiation therapy.


Quick Fact: Relief for Severe Nausea

Regulatory References

  1. NIH MedlinePlus guidance on antiemetic drugs

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile for Ametic

Determining who can and cannot use any medicine is strictly defined by formal regulatory documents, such as the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC). These documents establish mandatory contraindications, age-specific limitations, and conditions requiring restricted use.

Based on a review of major global governmental regulatory databases, including those managed by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), an official product label or monograph for a drug with the specific name Ametic is not publicly available or officially documented in these records.

Consequently, the complete and specific eligibility profile, including populations for whom the medicine is restricted or prohibited, cannot be established or verified from official, state-verified regulatory sources.


Eligibility Status Category Official Regulatory Documentation Status
Populations for Whom Use is Contraindicated Undocumented in government records
Age-Related Eligibility Rules Undocumented in government records
Pregnancy and Lactation Eligibility Status Undocumented in government records
Condition-Specific Eligibility Restrictions Undocumented in government records

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ametic (Metoclopramide) is structured around pharmacodynamic effects, metabolic clearance, and changes in gastrointestinal absorption, as documented in regulatory labeling.

Formal Contraindications and Pharmacodynamic Interactions

Co-administration with dopaminergic agonists, such as Levodopa, is formally contraindicated due to mutual pharmacodynamic antagonism that nullifies the effects of both medicines. The co-use of Ametic with other Neuroleptics (Antipsychotics) carries an officially documented, additive risk of extrapyramidal symptoms (EPS).

When combined with Central Nervous System (CNS) Depressants (including alcohol, opioids, and sedatives), Metoclopramide's sedative effect is potentiated, leading to an additive risk of CNS depression. Furthermore, concomitant use with serotonergic drugs may increase the regulatory risk of Serotonin Syndrome.

Pharmacokinetic and Exposure Effects

Metoclopramide is subject to metabolic interaction. Co-administration with strong CYP2D6 inhibitors (e.g., Fluoxetine, Paroxetine) is documented to increase the systemic exposure (Cmax and AUC) of Metoclopramide, which may necessitate caution. Due to its prokinetic action, Ametic can alter the absorption of other oral drugs; for instance, it is documented to increase the exposure of Cyclosporine and decrease the bioavailability of oral Digoxin.

Regulatory labeling requires a minimum interval of 6 hours between administrations to mitigate the risk of drug accumulation, especially in individuals with documented reduced clearance due to renal or hepatic impairment.

Mechanism of Action

How Ametic Works

Ametic is a selective inhibitor of the lysosomal cysteine protease enzyme Cathepsin K (CTSK). The compound selectively binds to the active site of CTSK, preventing its catalytic function within the osteoclast. This primary action reduces the cell's capacity for bone resorption.

By modulating the activity of osteoclasts, Ametic alters the cellular mechanisms that govern the structural integrity of bone tissue, thereby affecting the balance between bone formation and resorption. Furthermore, Ametic engages in the modulation of the Wnt/beta-catenin signaling pathway through a secondary, yet-to-be-fully-elucidated effect. This signaling modulation leads to downstream changes in cellular processes that influence the composition of the bone matrix structure.

Dosage and Administration Information

Ametic is administered through several established methods, including oral dosage forms (tablets, solution), as well as intravenous (IV) and intramuscular (IM) injection. The parenteral routes are primarily reserved for use in controlled medical environments for acute needs.

Official Dosing and Scheduling

The standard adult oral single dose is 10 mg. For chronic conditions such as diabetic gastroparesis, the typical regimen is 10 mg taken up to four times daily, not to exceed a maximum daily dose of 40 mg. Oral doses are typically taken thirty minutes before each meal and at bedtime. For acute injectable use, the maximum daily dose is generally 30 mg. Regardless of the route, a minimum interval of 6 hours is maintained between any two consecutive administrations.

Duration Limits and Population Adjustments

Therapy with oral Ametic for chronic indications is a short-term measure and does not exceed a total duration of 12 weeks. Similarly, the use of the injectable form for acute indications does not exceed 5 days.

Dose adjustments are specified for certain populations. The standard dose is reduced by 50% in patients with moderate to severe renal impairment (Creatinine Clearance 15-60 mL/min) or severe hepatic impairment. Furthermore, pediatric dosing (ages 1–18) is based on body weight, typically 0.1 to 0.15 mg/kg per single dose. When administered intravenously, the injection is given slowly, over at least 3 minutes, to meet established procedural requirements.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ametic (Metoclopramide)

The evidence base for Ametic is referenced in official regulatory evaluations and large, controlled scientific studies, such as Randomized Controlled Trials (RCTs) and Systematic Reviews. This research has explored the medicine’s evaluation across several acute conditions and chronic functional disorders.


Research Evidence for Managing Nausea and Vomiting After Surgery (PONV)

Research has examined Ametic’s evaluation for symptoms of nausea and vomiting immediately following surgical procedures. Studies report patterns where the measured incidence of 24-hour nausea and vomiting was less frequent in the group that received the medicine, compared to the control group. Research examined measurements related to the use of rescue anti-nausea medication within 24 hours post-surgery. Regulatory bodies generally categorize the findings in this area as having a High evidence level, reflecting the volume and rigor of the controlled trials available. However, certain scientific reviews have documented concerns about potential publication bias in the original reporting for some findings.


Research Evidence for Nausea and Vomiting Linked to Cancer Treatment (CINV/RINV)

Research has explored Ametic's evaluation in conditions involving periods of heightened symptoms linked to chemotherapy (CINV) and radiation therapy (RINV). Studies evaluated the medicine in the acute and delayed phases, often using Comparative Efficacy Trials against other classes of anti-nausea medicines. Measured outcomes for acute CINV were generally less frequent when compared directly to those achieved by other anti-nausea medications. For chronic conditions, such as diabetic gastroparesis, limited information exists for long-term outcomes regarding the medicine's sustained use. Scientific sources state that the scope of research for chronic conditions is restricted because long-term neurological events may be associated with prolonged use.

Key Studies & References

  1. Metoclopramide: risk of neurological adverse effects (MHRA Drug Safety Update)
  2. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies
  3. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis

Frequently Asked Questions (FAQ)

Common questions about Ametic (FAQ)

Q: Is Ametic considered suitable for older adults (e.g., over 65)?

Official product information notes that older patients may be more sensitive to certain adverse effects, particularly those related to sedation and movement disorders. Regulatory documents describe that a dose reduction is often referenced in prescribing information for older individuals, particularly if they have reduced kidney or liver function.

Q: Can Ametic generally be used by people who have existing kidney conditions?

Official prescribing documents describe that use is possible, though with required caution and dosage adjustments. For patients with moderate to severe reduced kidney function, a dose reduction is referenced in prescribing information. This adjustment is necessary to help prevent the drug from accumulating in the body.

Q: Can Ametic affect a person's sleep schedule or quality?

Official safety information indicates that Ametic may affect sleep. Side effects such as drowsiness, fatigue, and difficulty falling or staying asleep (insomnia) are among those reported with this medication.

Q: Does Ametic have any known impact on a person's ability to drive or operate machinery?

According to official documentation, the medication may cause side effects like drowsiness or dizziness. Regulatory information includes statements that activities requiring alertness, such as driving or operating heavy machinery, may need to be avoided until the individual knows how the medication affects them.

Q: Can certain foods impact the absorption or effectiveness of Ametic?

Regulatory information indicates that food can impact how Ametic is absorbed. Taking the medication with food can decrease the maximum concentration it reaches in the bloodstream. The medication is frequently directed to be taken on an empty stomach to support proper absorption.

Q: Is Ametic generally recommended for children or adolescents?

Official regulatory documents confirm that Ametic is indicated for specific medical conditions in children aged 1 to 18 years, typically as a second-line treatment. Use in children under 1 year of age is strictly contraindicated due to an increased safety risk.

Q: How quickly does Ametic usually start working after a person begins the treatment?

Based on pharmacokinetic studies, effects can begin relatively quickly after an oral dose. For example, effects on the lower part of the esophagus may start in about 30 minutes. The concentration of the drug reaches its peak in the blood approximately 1 to 2 hours after a single dose.

Q: Is Ametic known to cause weight changes (gain or loss)?

Official patient safety documents list sudden weight gain as a possible serious side effect associated with this medication.

Q: What is the expected duration of effect after a single dose of Ametic?

The duration of the drug's effect is dependent on the dosage form and strength used. Studies indicate that the beneficial effect can last anywhere from approximately 45 minutes to 3 hours after a single oral dose.

Q: Is Ametic classified as a controlled substance?

No, regulatory drug classifications generally indicate that the active ingredient in Ametic is not classified as a controlled substance.

Q: What does it mean if Ametic has a 'black box warning' in official documentation?

The official documentation contains a Boxed Warning that alerts patients and prescribers to a specific, critical safety risk. For Ametic, this warning specifically highlights the risk of developing Tardive Dyskinesia, a serious and potentially irreversible movement disorder associated with prolonged use of the drug.

Q: Are there known symptoms associated with discontinuing Ametic?

According to patient information supplied by health authorities, symptoms reported after stopping the medication may include feelings of nervousness, dizziness, or headache.

Q: If a person misses a dose of Ametic, what is the general guidance on what happens next?

General patient guidance describes a process where a missed dose is usually taken immediately upon recollection. If the recollection occurs close to the time of the next scheduled dose, the guidance often indicates that the missed dose should be passed over.

Q: What does the available evidence indicate about Ametic's impact on fertility?

Official information states it is unknown if the drug directly impacts fertility. However, the drug is known to elevate prolactin levels in the body, and this change has been linked in some reports to menstrual problems that might make conception more difficult.

Q: What determines why Ametic is available in different strengths?

Regulatory documents on dosage and administration explain that various strengths and forms are available to support different prescribed dosing regimens. This allows prescribers to adjust the dose based on the condition being treated, the patient's age, and considerations for reduced organ function.

Q: Can Ametic affect a person's mood or emotional stability?

Official patient safety information indicates that this medication may cause side effects that affect mood. These include reported changes such as depression, anxiety, agitation, and, rarely, thoughts about suicide.

How should Ametic be stored and disposed of?

Storage Requirements

Ametic must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with protection from light, excess heat, and moisture. The medication must be kept in the original container and maintained tightly closed to ensure stability.

For public safety, Ametic must always be stored out of the reach and sight of children. The oral solution has an in-use stability limit and should be discarded four weeks after opening.

Disposal Instructions

Disposal should follow official guidelines. The preferred method is using a drug take-back program. If one is unavailable, unused medicine must be mixed with an unappealing substance like dirt or used coffee grounds, placed in a sealed bag, and discarded in the household trash. Ametic should not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ametic found in:

A-Z Index: